CAR T cell therapy for children with lupus nephritis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the safety and potential efficacy of chimeric antigen receptor (CAR) T cell therapy in children aged 6 to 18 with refractory or recurrent lupus nephritis. It is a prospective, open-label, single-arm study that involves administering either low-dose or high-dose CAR T cells to participants. The study aims to assess the persistence and phenotype of CAR T cells in the body, as well as the inflammatory factors related to the treatment. The ultimate goal is to explore new therapeutic methods that can reduce the side effects of traditional treatments and improve long-term survival and quality of life for patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age 6-18 years old (including critical value);
2. Diagnosed with SLE according to the 2019 EULAR/ACR SLE classification criteria;
3. According to the 2018 ISN/RPS LN standards diagnosed with active Class III or IV LN, with or without a membranous component and the biopsy must be performed within 6 months prior to screening;
4. SLEDAI-2000 score ≥8 points;
5. Meeting the diagnosis of refractory lupus nephritis,

   1. defined as treatment with two or more immunosuppressants (including glucocorticoids, cyclophosphamide, tacrolimus, mycophenolic acid analogues, leflunomide, and cyclosporine) for more than 6 months without inducing remission or relapse after remission,
   2. accompanied by proteinuria without remission;
6. Positive expression of CD19 in peripheral blood B cells determined by flow cytometry;
7. Participants had good venous access, no contraindications for cell collection;
8. Participants and their guardians sign the informed consent, understand the study procedures and participate in the clinical study voluntarily;
9. The functions of important organs are basically normal:

   1. Hematopoietic function (blood routine should meet):

      * Lymphocyte count ≥1×109/L,
      * White blood cell count ≥3×109/L,
      * Neutrophil count ≥1×109/L (no colony-stimulating factor treatment within 2 weeks prior to examination),
      * Hemoglobin ≥60g/L;
   2. Liver function:

      * ALT≤3×ULN (except elevated ALT caused by inflammatory myopathy),
      * AST≤3×ULN (except for elevated AST caused by inflammatory myopathy),
      * TBIL≤1.5×ULN (except Gilbert syndrome, total bilirubin ≤3.0×ULN);
   3. Renal function: eGFR ≥30 ml/(min.1.73m2) (Schwartz formula, except abnormal renal function by SLE);
   4. Coagulation function:

      * International standardized ratio (INR) ≤1.5×ULN,
      * prothrombin time (PT) ≤1.5×ULN;
   5. Heart function: hemodynamic stability;
10. Anti-nuclear antibody (ANA) ≥1:80;
11. Eastern Cancer Cooperation Group (ECOG) physical status score 0 to 2.

Exclusion Criteria:

1. Received kidney transplant previously;
2. Serious drug allergy history or allergy;
3. Presence or suspicion of fungal, bacterial, viral or other infections that cannot be controlled or require treatment;
4. Complicated with severe organ dysfunction of heart, liver, lung or coagulation dysfunction;
5. Complicated with congenital immunoglobulin deficiency;
6. Participants with infectious diseases:

   1. Hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBc Ab) positive and peripheral blood hepatitis B virus (HBV) DNA titer greater than the normal reference value range;
   2. Hepatitis C virus (HCV) antibody positive and peripheral blood hepatitis C virus (HCV) RNA titer greater than the normal reference value range;
   3. Human immunodeficiency virus (HIV) antibody positive;
   4. Syphilis positive;
7. Diagnosed with malignant tumors in the last five years.
8. Suffer from severe central nervous system disease, mental illness and severe cognitive dysfunction;
9. Participated in other clinical trials within 3 months before enrollment;
10. Received CAR-T therapy previously;
11. Other situations that the researcher considers unsuitable for inclusion.

Where it's running

• Guangzhou Women and Children Medical Center
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: Xia Gao, M.D.
• Email: gaoxiagz@vip.163.com
• Phone: 86+020-81330569

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• TranspoCART19 CAR-T therapy in adults with refractory lupus nephritis

  This trial tests whether a patient’s own CD19 CAR-T cells can be safely given and potentially help adults with lupus nephritis that isn’t responding to standard treatments.

  Recruiting Phase 1/2 Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz · Badalona, Barcelona and 7 other locations · NCT07799116

• In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed or Refractory B-Cell Lymphoma

  This early-phase trial tests a one-time in vivo CAR T-cell therapy (SL1617) for people with relapsed or refractory B-cell lymphoma to see if it is safe and tolerable.

  Recruiting Phase 1 Chinese PLA General Hospital · Beijing · NCT07775508

• Biomarker-guided CAR-T target selection for refractory lupus

  This trial tests whether using a lab-based immune profile to pick CD19- or BCMA-targeted CAR-T can help adults with refractory lupus, including lupus nephritis, who have not responded to standard treatments.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07523542

• CD5 CAR T-cell therapy for relapsed or refractory T-cell lymphoma

  This trial tries CD5 CAR T-cell therapy, using either the patient's own cells or donor cells, and may bridge to stem-cell transplant for people 14–70 with relapsed or refractory T-cell lymphoma.

  Recruiting at 3 sites Phase 1/2 Beijing GoBroad Hospital · Beijing and 2 other locations · NCT07022964

• Glofitamab plus obinutuzumab for mantle cell lymphoma after CAR‑T

  This trial tests whether the antibody drug glofitamab given with obinutuzumab can shrink or control mantle cell lymphoma that returned or didn't respond after CD19 CAR‑T therapy in adults.

  Recruiting at 11 sites Phase 2 National Cancer Institute (NCI) · Duarte, California and 10 other locations · NCT07003295

• CD7 CAR T-Cell Therapy for T-Cell Lymphomas

  This study is testing a new CAR T-cell therapy for people with T-cell lymphomas that haven't responded to regular treatments to see if it is safe and effective.

  Recruiting at 4 sites Phase 1/2 Beijing GoBroad Hospital · Beijing, Beijing Municipality and 3 other locations · NCT06925464

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.